Published in J Neurochem on March 29, 2006
Control of brain development, function, and behavior by the microbiome. Cell Host Microbe (2015) 1.48
Granulocyte-colony stimulating factor improves outcome in a mouse model of amyotrophic lateral sclerosis. Brain (2008) 1.40
CNS-targeted viral delivery of G-CSF in an animal model for ALS: improved efficacy and preservation of the neuromuscular unit. Mol Ther (2010) 1.08
Bone marrow mesenchymal stem cells can be mobilized into peripheral blood by G-CSF in vivo and integrate into traumatically injured cerebral tissue. Neurol Sci (2011) 1.05
Long-term evaluation of granulocyte-colony stimulating factor on hypoxic-ischemic brain damage in infant rats. Intensive Care Med (2010) 0.98
Cell biology and clinical promise of G-CSF: immunomodulation and neuroprotection. J Cell Mol Med (2008) 0.86
Both systemic and local application of granulocyte-colony stimulating factor (G-CSF) is neuroprotective after retinal ganglion cell axotomy. BMC Neurosci (2009) 0.85
Soluble prokaryotic overexpression and purification of bioactive human granulocyte colony-stimulating factor by maltose binding protein and protein disulfide isomerase. PLoS One (2014) 0.83
Mobilisation of hematopoietic CD34+ precursor cells in patients with acute stroke is safe--results of an open-labeled non randomized phase I/II trial. PLoS One (2011) 0.83
Granulocyte-colony stimulating factor (G-CSF) improves motor recovery in the rat impactor model for spinal cord injury. PLoS One (2012) 0.82
Granulocyte-colony stimulating factor improves Parkinson's disease associated with co-morbid depression: an experimental exploratory study. Indian J Pharmacol (2013) 0.80
Synergetic effects of granulocyte-colony stimulating factor and cognitive training on spatial learning and survival of newborn hippocampal neurons. PLoS One (2009) 0.80
Protection of taurine and granulocyte colony-stimulating factor against excitotoxicity induced by glutamate in primary cortical neurons. J Biomed Sci (2010) 0.78
Granulocyte-colony stimulating factor improves MDX mouse response to peripheral nerve injury. PLoS One (2012) 0.77
Microglia-Mediated Neuroinflammation and Neurotrophic Factor-Induced Protection in the MPTP Mouse Model of Parkinson's Disease-Lessons from Transgenic Mice. Int J Mol Sci (2016) 0.76
Extending the serum half-life of G-CSF via fusion with the domain III of human serum albumin. Biomed Res Int (2013) 0.76
pH responsive granulocyte colony-stimulating factor variants with implications for treating Alzheimer's disease and other central nervous system disorders. Protein Eng Des Sel (2015) 0.75
Role of Endogenous Bone Marrow Stem Cells Mobilization in Repair of Damaged Inner Ear in Rats. Int J Stem Cells (2015) 0.75
Molecular Mechanism of Regulation of MTA1 Expression by Granulocyte Colony-stimulating Factor. J Biol Chem (2016) 0.75
Effect of granulocyte colony-stimulating factor on the peripheral nerves in streptozotocin-induced diabetic rat. Diabetes Metab J (2013) 0.75
Distribution of the hematopoietic growth factor G-CSF and its receptor in the adult human brain with specific reference to Alzheimer's disease. J Anat (2014) 0.75
G-CSF for mobilizing transplanted bone marrow stem cells in rat model of Parkinson's disease. Iran J Basic Med Sci (2016) 0.75
Granulocyte colony stimulating factor reduces brain injury in a cardiopulmonary bypass-circulatory arrest model of ischemia in a newborn piglet. Neurochem Res (2014) 0.75
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke (2009) 5.28
Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci (2002) 4.38
PML in a patient treated with fumaric acid. N Engl J Med (2013) 3.87
The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. J Clin Invest (2005) 3.22
Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons. Neuron (2009) 3.11
NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proc Natl Acad Sci U S A (2003) 2.91
Senataxin, the ortholog of a yeast RNA helicase, is mutant in ataxia-ocular apraxia 2. Nat Genet (2004) 2.75
Early outcome of carotid angioplasty and stenting with and without cerebral protection devices: a systematic review of the literature. Stroke (2003) 2.63
Intravenous brain-derived neurotrophic factor enhances poststroke sensorimotor recovery and stimulates neurogenesis. Stroke (2007) 2.54
Knockdown of transactive response DNA-binding protein (TDP-43) downregulates histone deacetylase 6. EMBO J (2009) 2.37
Delivery of bioactive molecules into the cell: the Trojan horse approach. Mol Cell Neurosci (2004) 2.36
Granulocyte colony-stimulating factor in patients with acute ischemic stroke: results of the AX200 for Ischemic Stroke trial. Stroke (2013) 2.36
Repetitive bilateral arm training and motor cortex activation in chronic stroke: a randomized controlled trial. JAMA (2004) 2.36
Genetic engineering of glomerular sclerosis in the mouse via control of onset and severity of podocyte-specific injury. J Am Soc Nephrol (2005) 2.33
Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Hum Mol Genet (2005) 2.28
D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease. J Clin Invest (2003) 2.25
Biological and clinical characteristics of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 in the longitudinal RISCA study: analysis of baseline data. Lancet Neurol (2013) 2.24
Monitoring regulated protein-protein interactions using split TEV. Nat Methods (2006) 2.24
Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle. Brain (2008) 2.18
Neuroprotective role of the Reaper-related serine protease HtrA2/Omi revealed by targeted deletion in mice. Mol Cell Biol (2004) 2.15
β-synuclein aggregates and induces neurodegeneration in dopaminergic neurons. Ann Neurol (2013) 2.10
Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models. EMBO J (2009) 2.09
JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A (2004) 2.05
Systematic review of early recurrent stenosis after carotid angioplasty and stenting. Stroke (2004) 2.04
An optical coherence tomography study on degeneration of retinal nerve fiber layer in rats with autoimmune optic neuritis. Invest Ophthalmol Vis Sci (2012) 2.02
Genetic dissection of the circuit for hand dexterity in primates. Nature (2012) 2.01
Meta-analysis of the efficacy of granulocyte-colony stimulating factor in animal models of focal cerebral ischemia. Stroke (2008) 1.93
Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. J Clin Invest (2004) 1.92
ROCK inhibition and CNTF interact on intrinsic signalling pathways and differentially regulate survival and regeneration in retinal ganglion cells. Brain (2007) 1.87
Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol (2002) 1.79
Initial lesion volume is an independent predictor of clinical stroke outcome at day 90: an analysis of the Virtual International Stroke Trials Archive (VISTA) database. Stroke (2012) 1.79
Cellular pathology of Parkinson's disease: astrocytes, microglia and inflammation. Cell Tissue Res (2004) 1.76
Combined laparoscopic-endoscopic resections of colorectal polyps: 10-year experience and follow-up. Surg Endosc (2009) 1.74
Administration of edaravone, a free radical scavenger, during t-PA infusion can enhance early recanalization in acute stroke patients--a preliminary study. J Neurol Sci (2011) 1.73
Short and long-term motor skill learning in an accelerated rotarod training paradigm. Neurobiol Learn Mem (2004) 1.72
Neuroprotection by hypoxic preconditioning requires sequential activation of vascular endothelial growth factor receptor and Akt. J Neurosci (2002) 1.72
Mechanisms of acute axonal degeneration in the optic nerve in vivo. Proc Natl Acad Sci U S A (2010) 1.70
Long-term effects of early-life environmental manipulations in rodents and primates: Potential animal models in depression research. Neurosci Biobehav Rev (2005) 1.70
Hyperglycemia independently increases the risk of early death in acute spontaneous intracerebral hemorrhage. J Neurol Sci (2007) 1.67
Efficient inhibition of the Alzheimer's disease beta-secretase by membrane targeting. Science (2008) 1.67
Transgenic rat model of Huntington's disease. Hum Mol Genet (2003) 1.66
Unexpected expression of alpha- and beta-globin in mesencephalic dopaminergic neurons and glial cells. Proc Natl Acad Sci U S A (2009) 1.64
Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J Neurochem (2004) 1.61
Pharmacological manipulation of peroxisome proliferator-activated receptor γ (PPARγ) reveals a role for anti-oxidant protection in a model of Parkinson's disease. Exp Neurol (2012) 1.60
Non-cell-autonomous roles for the planar cell polarity gene Vangl2 in development of the coronary circulation. Circ Res (2008) 1.60
Inhibition of Rho kinase (ROCK) increases neurite outgrowth on chondroitin sulphate proteoglycan in vitro and axonal regeneration in the adult optic nerve in vivo. J Neurochem (2007) 1.59
TDP-43-mediated neuron loss in vivo requires RNA-binding activity. PLoS One (2010) 1.58
Lack of the Kir4.1 channel subunit abolishes K+ buffering properties of astrocytes in the ventral respiratory group: impact on extracellular K+ regulation. J Neurophysiol (2005) 1.57
Molecular identity of periglomerular and short axon cells. J Neurosci (2010) 1.55
Effects of interferon-beta-1a on neuronal survival under autoimmune inflammatory conditions. Exp Neurol (2006) 1.55
Clinical predictors of transient ischemic attack, stroke, or death within 30 days of carotid angioplasty and stenting. Stroke (2005) 1.53
Loss of Dickkopf-1 restores neurogenesis in old age and counteracts cognitive decline. Cell Stem Cell (2013) 1.53
Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann Neurol (2002) 1.52
iTRAQ and multiple reaction monitoring as proteomic tools for biomarker search in cerebrospinal fluid of patients with Parkinson's disease dementia. Exp Neurol (2012) 1.52
Comparison between breast volume measurement using 3D surface imaging and classical techniques. Breast (2006) 1.51
Glutathione--a review on its role and significance in Parkinson's disease. FASEB J (2009) 1.50
The heart in Friedreich ataxia: definition of cardiomyopathy, disease severity, and correlation with neurological symptoms. Circulation (2012) 1.50
The up-regulation of microRNA-335 is associated with lipid metabolism in liver and white adipose tissue of genetically obese mice. Biochem Biophys Res Commun (2009) 1.49
Neuronal activation of NF-kappaB contributes to cell death in cerebral ischemia. J Cereb Blood Flow Metab (2005) 1.49
Dynamics of tyrosine hydroxylase promoter activity during midbrain dopaminergic neuron development. J Neurochem (2002) 1.48
Mechanisms and time course of neuronal degeneration in experimental autoimmune encephalomyelitis. Brain Pathol (2004) 1.45
Effect of erythropoietin axotomy-induced apoptosis in rat retinal ganglion cells. Invest Ophthalmol Vis Sci (2004) 1.44
Deep brain stimulation. Cell Tissue Res (2004) 1.42
Two molecular pathways initiate mitochondria-dependent dopaminergic neurodegeneration in experimental Parkinson's disease. Proc Natl Acad Sci U S A (2007) 1.41
TAT-BH4 and TAT-Bcl-xL peptides protect against sepsis-induced lymphocyte apoptosis in vivo. J Immunol (2006) 1.41
Granulocyte-colony stimulating factor improves outcome in a mouse model of amyotrophic lateral sclerosis. Brain (2008) 1.40
Penguins and hummingbirds: midbrain atrophy in progressive supranuclear palsy. Neurology (2006) 1.40
Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in mice. J Neurosci (2005) 1.40
A neuroprotective function for the hematopoietic protein granulocyte-macrophage colony stimulating factor (GM-CSF). J Cereb Blood Flow Metab (2007) 1.39
Motor skill learning depends on protein synthesis in motor cortex after training. J Neurosci (2004) 1.37
Down-regulation of apoptosis mediators by RNAi inhibits axotomy-induced retinal ganglion cell death in vivo. Brain (2005) 1.37
Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease. Acta Neuropathol (2013) 1.34
A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis. Ann Neurol (2012) 1.34
A lentiviral strategy for highly efficient retrograde gene transfer by pseudotyping with fusion envelope glycoprotein. Hum Gene Ther (2011) 1.34
Upregulation of cellular prion protein (PrPc) after focal cerebral ischemia and influence of lesion severity. Neurosci Lett (2004) 1.33
Visceral afferents directly activate catecholamine neurons in the solitary tract nucleus. J Neurosci (2007) 1.32